Osteoblastoma

Osteoblastoma is a rare benign bone-forming tumour in which active osteoblasts produce osteoid and immature woven bone. It accounts for about 1% of primary bone tumours and 3% of benign bone tumours. Histologically it resembles osteoid osteoma; it is distinguished by size greater than 2cm and by different clinical behaviour.

Why it matters. Four features make it clinically important:

• It can mimic malignant tumours radiologically and histologically, particularly in its aggressive variant
• Spinal involvement may cause neurological compromise
• It recurs locally, so it needs long-term surveillance
• Its treatment differs from that of osteoid osteoma, so the two must be told apart

Who. The peak age is 10-30 years, within a range of 2-75 years, and males are affected twice as often as females. There is no racial predilection.

Where. About 30-40% arise in the spine (32% in the 306-case Lucas series) and about 30% in the long bones, the remainder at other sites.

• Spine: the posterior elements, namely pedicle, lamina and transverse process
• Long bones: femur and tibia, in the metaphysis or diaphysis
• Other sites: mandible, hands and feet, less commonly
• Epiphysis: rare, under 5% of cases

The molecular event. The defining molecular event is now established: recurrent rearrangements of FOS, and less commonly FOSB, are present in the great majority of osteoblastomas and osteoid osteomas, placing the two lesions in a single molecular family. These rearrangements are absent in osteosarcoma, so FOS immunohistochemistry (or FOS/FOSB FISH) is a useful ancillary test when morphology alone cannot separate an aggressive osteoblastoma from a bone-forming sarcoma.

Microscopy. Uniform osteoblasts line the osteoid seams and produce abundant immature osteoid and woven bone with irregular mineralisation. The stroma is highly vascular fibrous tissue, with scattered osteoclast-like giant cells.

View larger

The aggressive variant. Approximately 10-15% of osteoblastomas show aggressive histological features: epithelioid osteoblasts, sheet-like growth and increased mitotic activity. This variant recurs more often and can be misdiagnosed as osteosarcoma.

The pain. The classic presentation is progressive bone pain over weeks to months: constant, moderate to severe, and often worse at night. Unlike osteoid osteoma, the pain is typically not relieved by aspirin or NSAIDs, a key difference between the two.

Spinal lesions. A spinal lesion may present with radicular pain, motor weakness or scoliosis, and can cause neurological deficit from mass effect or pathological fracture. The neurological features to look for:

• Radiculopathy from nerve root compression
• Motor weakness in a myotomal distribution and dermatomal numbness
• Painful scoliosis in children
• Cauda equina compression, which is rare, with lower lumbar lesions

Examination. The overlying skin is normal, without warmth or redness. The rest of the examination, step by step:

• Look: swelling, visible if the lesion is superficial (hands, feet); scoliosis with spinal lesions; an antalgic gait if the lower limb is involved
• Feel: localised bony tenderness; a mass, palpable if the cortex is expanded; distal pulses and sensation
• Move: range limited by pain if the lesion is juxta-articular; strength reduced by pathological fracture or nerve compression; a full neurological examination (motor, sensory, reflexes) if spinal
• Special tests: straight leg raise and the neurological level for spinal lesions, stability assessment for a pathological fracture, and the Adams forward-bend test for scoliosis

Osteoid production. Osteoblastoma produces osteoid, which separates it from an aneurysmal bone cyst (fluid-fluid levels on MRI, no osteoid) and, together with the younger age, from a giant cell tumour. Two further lesions belong on the list:

• Bone island (enostosis): dense and sclerotic, no expansion, asymptomatic
• Chondroblastoma: epiphyseal, chondroid matrix, younger age

Treatment follows biopsy-confirmed diagnosis, Enneking stage, anatomical accessibility and neurological risk. Active contained lesions require complete intralesional excision; aggressive, recurrent or structurally destructive lesions favour en-bloc resection with planned reconstruction.

Stage 2 (Active)Stage 3 (Aggressive)Spinal Osteoblastoma

The goal. Complete removal of the lesion with bone preservation and a low risk of recurrence.

Before surgery. CT and MRI map the lesion precisely, and the case goes to a tumour board of surgeon, radiologist, pathologist and oncologist. Counsel the patient about the recurrence risk, and plan for reconstruction if it will be needed.

The operation.

1. Open a cortical window for access
2. Curette the entire lesion thoroughly
3. Remove 1-2mm of the cavity wall with a high-speed burr
4. Apply a local adjuvant (phenol or argon beam)
5. Fill the cavity with bone graft (autograft or allograft) or PMMA cement, which provides a thermal adjuvant effect
6. Fix prophylactically if the mechanical defect exceeds 50% of the cortex, then close over a drain

Adjuvant Options

Local adjuvants are used to kill microscopic residual tumour at the cavity wall:

• Phenol: applied to the cavity wall for 2-3 minutes, then irrigated with alcohol and saline
• PMMA cement: thermal necrosis from polymerisation, which reaches 70-80°C
• Argon beam coagulation: superficial thermal ablation of the cavity

No comparative study has measured what adjuvants add in osteoblastoma. The practice is extrapolated from giant cell tumour and from the general principle that recurrence follows residual tumour at the cavity wall; the recurrence figures quoted for osteoblastoma come from uncontrolled series in which adjuvant use was neither standardised nor recorded, so no number can be attached to the benefit.

The goal. Wide resection with negative margins, to minimise recurrence.

Indications for en bloc resection.

• Aggressive histological features on biopsy
• Cortical breakthrough with soft-tissue extension
• Recurrent disease after intralesional treatment
• An expendable bone (proximal fibula, rib)

The resection. En bloc, with a 1-2cm margin, the biopsy tract included in the specimen and the margins sent for frozen section. Assess the need for reconstruction.

Reconstruction. Expendable bones such as the fibula or a rib need none. Structural bones are reconstructed with allograft, autograft or endoprosthesis, and the spine with decompression and instrumented fusion; the choice weighs patient age, activity level and location.

Aggressive Variant Management

Aggressive osteoblastoma with epithelioid features requires en bloc resection because it recurs more often after intralesional treatment. However, it does NOT metastasise and should not receive chemotherapy or radiation. Distinguish it from osteosarcoma by its circumscribed margin and lack of permeative growth.

The goal. Neural decompression, tumour removal and restoration of spinal stability.

Neurological assessment. Measure the degree of canal compromise on MRI and document motor, sensory, bowel and bladder function. A progressive deficit is an indication for urgent surgery.

The posterior approach. The standard route: laminectomy for decompression if the canal is compromised, en bloc or intralesional excision of the lesion, and instrumented fusion if the resection destabilises the spine, all under intraoperative neuromonitoring (SSEP, MEP).

Reconstruction. Pedicle screw fixation 2 levels above and below, with posterolateral fusion and bone graft. Consider anterior column support if the vertebral body is involved, and brace postoperatively according to stability.

View larger

View larger

View larger

View larger

View larger

What helps. Preoperative embolisation if the lesion is highly vascular, intraoperative navigation for pedicle screw placement, neuromonitoring to alert the team to neural compromise, and a cell saver for blood conservation. Complete excision reduces the recurrence risk.

Pitfalls to avoid.

• Inadequate decompression, causing a persistent deficit
• An unstable construct after a destabilising resection
• Incomplete tumour excision, leading to recurrence
• Injury to the exiting nerve roots
• Inadequate fusion, leading to pseudarthrosis

Non-surgical management. There is no role for chemotherapy or radiation in the primary treatment of osteoblastoma, because it is a benign tumour. These modalities may be considered only in exceptional circumstances.

Local recurrence. Recurrence after intralesional treatment is conventionally quoted as 10-20%, though the largest series reports 16% in institutional cases and 21% in referred consultation material (Lucas 1994); the upper figure sits above the conventional range and is inflated by referral bias. For the aggressive variant treated intralesionally the figure quoted is 25-50%, and it is an unverified range: Lucas found histology alone did not predict behaviour. Incomplete excision and aggressive histology are the risk factors; recurrence is treated by revision surgery, considering en bloc resection.

View larger

View larger

Favourable prognosis. Complete excision with negative margins, classic histology without aggressive features, and an accessible location amenable to complete resection. Small size (under 5cm) and a peripheral site such as the hand or foot, where excision is easier, also favour a good outcome.

Poor prognosis. Aggressive histology (epithelioid features, increased mitoses), incomplete excision with residual tumour, and a spinal location where complete excision is difficult. Large size (over 10cm) and recurrent disease, which carries a higher re-recurrence rate, also count against the patient.

Global epidemiology: Osteoblastoma is rare, accounting for about 1% of all primary bone tumours and roughly 3% of benign bone tumours, with a consistent worldwide picture of peak incidence in the second and third decades and a male predominance of about 2:1. The spinal predilection (30-40%, 32% in the largest series) is reported across North American, European and Asian cohorts, indicating no major geographic variation in biology.

Side-by-side guidance: There is no osteoblastoma-specific guideline; practice is governed by general bone-tumour pathways.

Registries: Osteoblastoma is benign and is not tracked by the arthroplasty registries (NJR, AJRR, AOANJRR, SHAR); incidence and outcome data come instead from national bone-tumour and pathology reference centres (for example the Mayo, Rizzoli and Royal National Orthopaedic Hospital series).

High- vs limited-resource practice: In high-resource settings, thin-slice CT, MRI, image-guided biopsy, FOS/FOSB ancillary testing and specialist musculoskeletal pathology are standard, allowing confident separation from osteosarcoma before surgery. In limited-resource settings, diagnosis may rest on plain radiographs and conventional histology, raising the risk of either under-treating a low-grade osteosarcoma or over-treating a benign lesion; referral of indeterminate bone-forming lesions to a tumour centre remains the universal safeguard.

Related pages: Osteoid Osteoma for the lesion osteoblastoma is separated from by size and NSAID response — note the two share FOS/FOSB rearrangement and are one molecular family, so the distinction remains clinical and radiological rather than genetic; Osteosarcoma for the mimic that matters, and the reason FOS immunohistochemistry is worth requesting; Aneurysmal Bone Cyst for the secondary change frequently seen within an osteoblastoma and for the USP6 rearrangement that separates a primary ABC from it; Giant Cell Tumor of Bone for the lesion whose adjuvant curettage technique this page's practice is extrapolated from; Primary Bone Tumors of the Spine for the site that accounts for about a third of cases; and Describing a Bone Tumour Radiograph and Predicting Bone Tumour by Age for the systematic approach that reaches this diagnosis.

Osteoblastoma generates several genuine debates that examiners use to probe depth of understanding.

Osteoblastoma, like osteoid osteoma, is a classic cause of painful scoliosis in the adolescent, and this topic's examination steps — the Adams forward-bend test and a "painful curve with apical lesion" — depend on understanding the mechanism. When a bone-forming lesion sits in the posterior elements of a vertebra, reflex ipsilateral paravertebral muscle spasm pulls the spine into a curve whose apex lies at the lesion and whose concavity points toward the tumour; the lesion is therefore found on the concave side at or immediately adjacent to the apical vertebra. Early in its course this is a non-structural (functional) curve driven by pain and spasm rather than fixed vertebral wedging, so it lacks the rigid rotational deformity of adolescent idiopathic scoliosis.

The practical consequence is that complete excision of the lesion can allow the curve to resolve, particularly when the patient is skeletally immature and symptoms have been present for a relatively short time. Longstanding curves may instead become structural and fixed, persisting or requiring separate deformity correction even after the tumour is removed. A rigid, painful, or otherwise atypical curve in a child — especially a left thoracic curve or one with a marked painful component — should therefore prompt a search for an underlying osteoid osteoma or osteoblastoma with thin-slice CT of the concave apex, rather than a default label of idiopathic scoliosis. (Osteoid-osteoma-related scoliosis is developed on its own topic; the focus here is the larger, more destructive osteoblastoma lesion in the posterior elements.)

The management sections twice raise preoperative embolisation "if highly vascular", and a viva follow-up explicitly asks its role, but the rationale is worth stating: osteoblastoma has a prominent, dilated vascular stroma (as noted in its histology) that can make resection of large spinal, sacral or pelvic lesions bloody. Selective transarterial embolisation, performed a day or two before surgery, occludes the dominant feeding vessels so that intraoperative haemorrhage is reduced and the operative field is clearer, which in turn supports the complete resection that is the single best predictor of avoiding recurrence.

Embolisation is an adjunct, never a cure — it does not destroy the tumour and is no substitute for excision. It is most useful for hypervascular lesions of the spine and sacrum, where blood loss can otherwise be substantial and where a cleaner field protects neural structures during decompression. Limitations include the risk of embolising vessels that also supply the spinal cord (the artery of Adamkiewicz and radicular cord-feeders must be identified and protected on spinal angiography), non-target embolisation, and post-embolisation pain and low-grade fever. Because collateral supply re-forms quickly, surgery should follow promptly, generally within about 24 to 48 hours.